3de Boer H,Jansen M,Koerts J,et al. Prevention of weight gain in-type 2 diabetes requiring insulin treatment[J]. Diabetes Obes Metab, 2004,6(2):114-119.
二级参考文献15
1Ebeling P, Jansson P A, Smith U, et al. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin[J]. Diabetes Care, 1997,20 : 1287-1289.
2Rosskamp R H, Park G. Long-acting insulin analogs[J].Diabetes Care,1999, 22(Suppl 2) :B109-B113.
3Vajo Z, Fawcett J, Duckworth W C. Recombinant DNA technology in the treatment of diabetes [ J]. Endocr Rev, 2001,22:706-717.
4McKeage K, Goa K L. Insulin Glargine [ J ]. Drugs, 2001,61 :1599-1624.
5Heinemann L, Linkeschova R, Rave K. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo[J]. Diabetes Care, 2000,23 : 644-649.
6Talaulicar M, Willms B, Rosskamp R. HOE901, ein neues insulin analog zur substitution des basalen insulin-bedarfs bei type 1 diabetes[ J ]. Diabetes Stoffwechsel, 1996,5 : 3-6.
7Ratner R E, Hirsch I B, Neifing J L. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes[J]. Diabetes Care ,2000,23 : 639-643.
8Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes [ J ] .Diabetes Care,2000,23 : 1130-1136.
9Hershon K, Blevins T, Donley D, et al. Lower fasting blood glucose(FBG) and less symptomatic hypoglycemia with QD insulin glargine(Lautus) compare to bid NPH insulin in subjects with type 1 diabetes[J]. Diabetes,2001,50( Suppl 2) :116-117.
10Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine compared to bedtime NPH insulin in patients with type 2 diabetes [ J] . Diabetes, 2001,50(Suppl 2) : 112-113.
1Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added oral agents versus twice-daily premixed insulin as initiaI insulin therapy for type 2 diabetes[J]. Diabetes Care,2005,28(2) :254-259.
3Kawamori R.Effects of repluingmetforminwith ploflitazone ongly-cemic control in Jaranese patientswith poorly controued type2 dia-betesmeccitus:A 12-week,oken-lake,l kroskectiue study[J].Diabetes Res Clin Pract,2008,79(1):97-102.
4Arechavaleta R,Seek T,Chen Y,et al.Efficacy and safety oftreatment with sitagliptin or glimepiride in patients with type 2diabetes inadequately controlled on metformin monotherapy:arandomized,double-blind,non-inferiority trial[J].Diabetes ObesMetab,2011,13(2):160-168.
6Janka HU,Plewe G,Riddle MC,et al.Comparion of basal insulin added to oral agents versulin therapy premixed insulin as initial insulin therapy for type 2 diabetes.Diabetes Care,2009,28:254-259.
7Hasslacher C,Collenberg E,M(o)eks J.Effect of insulin analogs on the decline of hemoglobin in diabetic patients with nephropathy.Exp Clini Endocrinolo Diabetes,2010,118:341-345.
